Profile | GDS2987 / GI_7382457-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 8 | 28 |
GSM215244 | HMVEC_vehicle_rep2 | 16.6 | 40 |
GSM215253 | HMVEC_vehicle_rep3 | 13.9 | 42 |
GSM215254 | HMVEC_atorvastatin_rep1 | 0.9 | 2 |
GSM215282 | HMVEC_atorvastatin_rep3 | ||
GSM215344 | HMVEC_atorvastatin_rep2 | 5.5 | 14 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 39.2 | 58 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | ||
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 19.7 | 32 |
GSM215294 | HMVEC_SLx2119_rep1 | 11.5 | 39 |
GSM215295 | HMVEC_SLx2119_rep2 | ||
GSM215296 | HMVEC_SLx2119_rep3 | 23.4 | 37 |
GSM215297 | PASMC_vehicle_rep1 | ||
GSM215298 | PASMC_vehicle_rep2 | 15 | 23 |
GSM215310 | PASMC_vehicle_rep3 | 47 | 59 |
GSM215311 | PASMC_atorvastatin_rep1 | ||
GSM215312 | PASMC_atorvastatin_rep2 | 38.8 | 52 |
GSM215313 | PASMC_atorvastatin_rep3 | 37.6 | 49 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 36.6 | 52 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 16.2 | 31 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 17.5 | 29 |
GSM215327 | PASMC_SLx2119_rep1 | ||
GSM215328 | PASMC_SLx2119_rep2 | 11.3 | 21 |
GSM215329 | PASMC_SLx2119_rep3 | ||
GSM215330 | Fibroblasts_vehicle_rep1 | 19.2 | 41 |
GSM215331 | Fibroblasts_vehicle_rep2 | 29 | 58 |
GSM215332 | Fibroblasts_vehicle_rep3 | 6 | 21 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 0.6 | 2 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 5.5 | 16 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | ||
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 25.7 | 59 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 6.7 | 22 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 13.5 | 36 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 7.9 | 23 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 12.2 | 33 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 13.9 | 34 |